Treatment of Erythrodermic Psoriasis with Infliximab and Etanercept in Two Cases

In the last two months, he has a dry desquamative EP (PASI: 32.8) with arthritis of both ankles. Laboratory test before biologic treatment were normal. He received subcutaneous injection of etanercept 50mg × 2 / week. At week 12, a clinical improvement in the patient condition was observed. Erythematic, scaling and itching showed a rapid response, with significantly reducing the PASI score to 7 (Figure 1). Case 2: A male patient 45 years old, with a history of colitis ulcerosa, an idiopathic thrombocytopenic purpura, and a primary sclerosing cholangitis. He has psoriasis since he was 26 years old. He received methotrexate, retinoid, and phototherapy without improvement. In the last 4 months, he developed a dry desquamative EP (PASI:37) with arthritis of both knees. Laboratory test before biologic treatment were normal except for thrombocytopenia: 109,000 / mm3. He received intravenous infusion of infliximab at a dose of 5mg / kg. At the third infusion, a significant improvement of EP was noted (PASI: 4,8) with a remission of arthritis (Figure 2).